Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

13.08.25 18:00 Uhr

BENSALEM, Pa., Aug. 13, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NOVO NORDISK A/S (NVO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE SEPTEMBER 30, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Is The Lawsuit About?
The complaint filed alleges that, between May 7, 2025, to July 28, 2025, Defendants failed to disclose to investors that: (1) Novo Nordisk repeatedly ignored and minimized the significance of the personalization exception for GLP-1 compounding, greatly overestimated its ability to capture patients coming off of compounded treatments, and was ultimately ill equipped to capitalize upon the purported significant unmet patient population; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:  

If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:
Howard G. Smith, Esq.,
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Call us at: (215) 638-4847
Email us at: howardsmith@howardsmithlaw.com,
Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Cision View original content:https://www.prnewswire.com/news-releases/novo-nordisk-as-nvo-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302528563.html

SOURCE Law Offices of Howard G. Smith

Nachrichten zu Novo Nordisk (spons. ADRs)

Wer­bung

Analysen zu Novo Nordisk (spons. ADRs)

DatumRatingAnalyst
20.06.2019Novo Nordisk (spons ADRs) HoldDeutsche Bank AG
11.06.2019Novo Nordisk (spons ADRs) Equal WeightBarclays Capital
15.10.2012Novo Nordisk kaufenEuro am Sonntag
26.07.2012Novo Nordisk neutralExane-BNP Paribas SA
08.06.2012Novo Nordisk neutralSarasin Research
DatumRatingAnalyst
15.10.2012Novo Nordisk kaufenEuro am Sonntag
30.04.2012Novo Nordisk buyCitigroup Corp.
09.07.2007Novo Nordisk kaufen und liegenlassenGlobal Biotech Investing
14.12.2006Update Novo Nordisk A/S (Spons. ADRS): BuyCitigroup
08.12.2005Update Novo Nordisk A/S (Spons. ADRS): OutperformBear Stearns
DatumRatingAnalyst
20.06.2019Novo Nordisk (spons ADRs) HoldDeutsche Bank AG
11.06.2019Novo Nordisk (spons ADRs) Equal WeightBarclays Capital
26.07.2012Novo Nordisk neutralExane-BNP Paribas SA
08.06.2012Novo Nordisk neutralSarasin Research
18.05.2012Novo Nordisk equal-weightMorgan Stanley
DatumRatingAnalyst
30.05.2012Novo Nordisk underperformCheuvreux SA
22.03.2012Novo Nordisk sellDeutsche Bank AG
22.03.2012Novo Nordisk reduceNomura
21.02.2012Novo Nordisk reduceNomura
30.01.2012Novo Nordisk reduceNomura

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novo Nordisk (spons. ADRs) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen